Multiple Myeloma Clinical Trials

A listing of 208 Multiple Myeloma clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Conditions

Multiple Myeloma

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

There are currently 208 active clinical trials seeking participants for Multiple Myeloma research studies. The states with the highest number of trials for Autism participants are California, New York, Ohio and Texas.

Featured Trial

Major Depressive Disorder Clinical Study

Recruiting

Is depression weighing you down? Local major depressive disorder clinical studies are now enrolling participants in the area. Participating in research studies helps contribute to the advancement of future medicine and treatment options. There is no obligation to take part and health insurance is not required.

Conditions:

Major Depressive Disorder

Major Depression

Major Depressive Episode

Major Depressive Disorder (MDD)

Major Depressive Disorders

Learn More

Featured Trial

Hyperacusis Activities Treatment-Online Study

Recruiting

Are you experiencing hyperacusis? If so, we are recruiting adults with hyperacusis to complete a clinical trial supported by the National Institutes of Health. The study involves participating in a remote counseling program and sound therapy trial for hyperacusis, Hyperacusis Activities Treatment-Online.

Conditions:

Hyperacusis

Tinnitus

Hearing Loss

Learn More

Real World Insights During Treatment for Relapsed/Refractory Multiple Myeloma With Isatuximab

NCT05053607

Recruiting

This descriptive study aims to evaluate the experience of adults with relapsed or refractory multiple myeloma receiving standard of care isatuximab-irfc through collection of quantitative, qualitative and wearable data. Fifty adults with relapsed or refractory multiple myeloma receiving standard of care isatuximab-irfc will be enrolled across 2 sites, The University of California San Francisco and The University of Texas MD Anderson Cancer Center. Consented participants will be enrolled in a 3-month digital health coaching program through which electronic patient reported outcomes and wearable activity data will be collected. Outcomes include treatment experience, quality of life, financial toxicity, treatment adherence, symptom burden and health self-efficacy. These will be captured by patient reported outcome measures including the Patient's Qualitative Assessment of Treatment- Real World (PQAT-RW), Patient Global Impression of Change/Severity (PGIC/S), European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30), Quality of Life Questionnaire Multiple Myeloma (QLQ-MY20), and the European QoL-5 Dimensions (EQ5D), Cancer Behavior Inventory-Brief Form (CBI-B), Center for Adherence Support Evaluation (CASE) Medication Adherence Index, Comprehensive Score for Financial Toxicity (COST) Instrument. Clinical data, including treatment history, healthcare utilization, and co-morbidities, as well as demographic data will be collected via the electronic health record from each clinical site. This data will be complemented by qualitative data from a selected cohort of study participants with a focus on treatment experience ranging from infusion burden, toxicity management, to overall quality of life. Evaluation of this data in combination will be used to better understand the treatment experience of individuals on standard of care isatuximab-irfc specifically, and with relapsed or refractory multiple myeloma generally, contributing to an existing gap in the literature regarding patient reported outcomes from diverse data sources. Outcomes will be analyzed with attention to the relationship between social determinants of health, including race, ethnicity, and geographic location, and treatment experience as reflected in both the qualitative and quantitative data. Read Less

Gender:

All

Ages:

18 years and above

Trial Updated:

05/11/2023

Locations: The University of Texas MD Anderson Cancer Center, Houston, Texas +1 locations

Conditions: Multiple Myeloma, Refractory Multiple Myeloma

Learn More ›

Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT01665794

Recruiting

The study will investigate the effects of adding carfilzomib to the combination of pomalidomide and dexamethasone in sequential dose escalation cohorts in patients with relapsed or refractory multiple myeloma. This portion of the study is complete. This study will also investigate the effects of adding daratumumab to the combination of carfilzomib, pomalidomide and dexamethasone.

Gender:

All

Ages:

18 years and above

Trial Updated:

04/26/2023

Locations: University of Chicago Comprehensive Cancer Center, Chicago, Illinois +4 locations

Conditions: Multiple Myeloma

Learn More ›

Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma

NCT03500445

Recruiting

The purpose of this study is to determine response rate after 8 cycles of D-KRd (daratumumab, carfilzomib, lenalidomide (Revlimid) and dexamethasone in patients with multiple myeloma.

Gender:

All

Ages:

18 years and above

Trial Updated:

04/26/2023

Locations: The University of Chicago, Chicago, Illinois

Conditions: Myeloma, Multiple Myeloma

Learn More ›

Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA)

NCT03729804

Recruiting

This is a randomized multicenter study that will compare two treatment regimens (Kyprolis, Revlimid, dexamethasone -KRD vs. Velcade, Revlimid, dexamethasone -VRD) for patients with newly diagnosed multiple myeloma.

Gender:

All

Ages:

18 years and above

Trial Updated:

04/26/2023

Locations: University Of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois

Conditions: Multiple Myeloma

Learn More ›

Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma

NCT05064358

Recruiting

This study aims to evaluate alternative dosing regimens of single-agent belantamab mafodotin in participants with relapsed or refractory multiple myeloma (RRMM) to determine if an improved overall benefit/risk profile can be achieved by modifying the belantamab mafodotin dose, schedule, or both.

Gender:

All

Ages:

18 years and above

Trial Updated:

04/10/2023

Locations: GSK Investigational Site, New Port Richey, Florida +102 locations

GSK Investigational Site, New Port Richey, Florida

GSK Investigational Site, West Palm Beach, Florida

GSK Investigational Site, Kansas City, Missouri

GSK Investigational Site, New York, New York

GSK Investigational Site, Chattanooga, Tennessee

GSK Investigational Site, Nashville, Tennessee

GSK Investigational Site, Houston, Texas

GSK Investigational Site, Spokane, Washington

GSK Investigational Site, Capital Federal, Buenos Aires

GSK Investigational Site, Rosario, Santa Fe

GSK Investigational Site, Ciudad Autonoma de Buenos Aires, Not set

GSK Investigational Site, Liverpool, New South Wales

GSK Investigational Site, Waratah, New South Wales

GSK Investigational Site, Woodville, South Australia

GSK Investigational Site, East Melbourne, Victoria

GSK Investigational Site, Salvador, Bahía

GSK Investigational Site, Curitiba, Paraná

GSK Investigational Site, Porto Alegre, Rio Grande Do Sul

GSK Investigational Site, Joinville, Santa Catarina

GSK Investigational Site, Rio de Janeiro, Not set

GSK Investigational Site, São Paulo, Not set

GSK Investigational Site, Oshawa, Ontario

GSK Investigational Site, Toronto, Ontario

GSK Investigational Site, Montreal, Quebec

GSK Investigational Site, Montréal, Quebec

GSK Investigational Site, Avignon cedex 9, Not set

GSK Investigational Site, Le Mans, Not set

GSK Investigational Site, Nice Cedex 2, Not set

GSK Investigational Site, Orléans, Not set

GSK Investigational Site, Saint-Priest en Jarez, Not set

GSK Investigational Site, Karlsruhe, Baden-Wuerttemberg

GSK Investigational Site, Cottbus, Brandenburg

GSK Investigational Site, Greifswald, Mecklenburg-Vorpommern

GSK Investigational Site, Oldenburg, Niedersachsen

GSK Investigational Site, Dortmund, Nordrhein-Westfalen

GSK Investigational Site, Dresden, Sachsen

GSK Investigational Site, Hamburg, Not set

GSK Investigational Site, Athens, Not set

GSK Investigational Site, Haidari, Athens, Not set

GSK Investigational Site, Rio/Patras, Not set

GSK Investigational Site, Thessaloniki, Not set

GSK Investigational Site, Nashik, Maharashtra

GSK Investigational Site, Ahmedabad, Not set

GSK Investigational Site, Bangalore, Not set

GSK Investigational Site, Hyderabad, Not set

GSK Investigational Site, Kerala, Not set

GSK Investigational Site, Kolkata, Not set

GSK Investigational Site, Mumbai, Not set

GSK Investigational Site, Pondicherry, Not set

GSK Investigational Site, Pune, Not set

GSK Investigational Site, Dublin, Not set

GSK Investigational Site, Bologna, Emilia-Romagna

GSK Investigational Site, Cona (FE), Emilia-Romagna

GSK Investigational Site, Meldola, Emilia-Romagna

GSK Investigational Site, Reggio Emilia, Emilia-Romagna

GSK Investigational Site, Rimini, Emilia-Romagna

GSK Investigational Site, Genova, Liguria

GSK Investigational Site, Ascoli Piceno, Marche

GSK Investigational Site, Alessandria, Piemonte

GSK Investigational Site, Cagliari, Not set

GSK Investigational Site, Busan, Not set

GSK Investigational Site, Hwasun-gun, Jeollanam-do, Not set

GSK Investigational Site, Seoul, Not set

GSK Investigational Site, Mexico City, Ciudad De Mexico

GSK Investigational Site, Mexico, Ciudad De Mexico

GSK Investigational Site, Bydgoszcz, Not set

GSK Investigational Site, Gdansk, Not set

GSK Investigational Site, Katowice, Not set

GSK Investigational Site, Lublin, Not set

GSK Investigational Site, Nowy Sacz, Not set

GSK Investigational Site, Walbrzych, Not set

GSK Investigational Site, Warszawa, Not set

GSK Investigational Site, Wroclaw, Not set

GSK Investigational Site, Oviedo, Asturias

GSK Investigational Site, Albacete, Not set

GSK Investigational Site, Alcorcón (Madrid), Not set

GSK Investigational Site, Barcelona, Not set

GSK Investigational Site, Cordoba, Not set

GSK Investigational Site, Gerona, Not set

GSK Investigational Site, Lleida, Not set

GSK Investigational Site, Terrassa (Barcelona), Not set

GSK Investigational Site, Valencia, Not set

GSK Investigational Site, Bern, Not set

GSK Investigational Site, Taichung, Not set

GSK Investigational Site, Tainan, Not set

GSK Investigational Site, Taipei, Not set

GSK Investigational Site, Bangkok, Not set

GSK Investigational Site, Chiang Mai, Not set

GSK Investigational Site, Khon Kaen, Not set

GSK Investigational Site, Stoke-on-Trent, Staffordshire

GSK Investigational Site, Leicester, Not set

GSK Investigational Site, London, Not set

Conditions: Multiple Myeloma

Learn More ›

Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders

NCT01758042

Recruiting

The main purpose of this study is to examine the outcome of a combined bone marrow and kidney transplant from a partially matched related (haploidentical or "haplo") donor. This is a pilot study, you are being asked to participate because you have a blood disorder and kidney disease. The aim of the combined transplant is to treat both your underlying blood disorder and kidney disease. We expect to have about 10 people participate in this study. Additionally, because the same person who is donating the kidney will also be donating the bone marrow, there may be a smaller chance of kidney rejection and less need for long-term use of anti-rejection drugs. Traditionally, very strong cancer treatment drugs (chemotherapy) and radiation are used to prepare a subject's body for bone marrow transplant. This is associated with a high risk for serious complications, even in subjects without kidney disease. This therapy can be toxic to the liver, lungs, mucous membranes, and intestines. Additionally, it is believed that standard therapy may be associated with a higher risk of a complication called graft versus host disease (GVHD) where the new donor cells attack the recipient's normal body. Recently, less intense chemotherapy and radiation regimens have been employed (these are called reduced intensity regimens) which cause less injury and GVHD to patients, and thus, have allowed older and less healthy patients to undergo bone marrow transplant. In this study, a reduced intensity regimen of chemotherapy and radiation will be used with the intent of producing fewer toxicities than standard therapy. Typical therapy following a standard kidney transplant includes multiple lifelong medications that aim to prevent the recipient's body from attacking or rejecting the donated kidney. These are called immunosuppressant drugs and they work by "quieting" the recipient's immune system to allow the donated kidney to function properly. One goal in our study is to decrease the duration you will need to be on immunosuppressant drugs following your kidney transplant as the bone marrow transplant will provide you with the donor's immune system which should not attack the donor kidney. Read Less

Gender:

All

Ages:

Between 18 years and 70 years

Trial Updated:

03/13/2023

Locations: Massachusetts General Hospital, Boston, Massachusetts

Conditions: Chronic Kidney Disease, Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Chronic Myelogenous Leukemia (CML), Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL), Hodgkin Disease, Multiple Myeloma, Myelodysplastic Syndrome (MDS), Aplastic Anemia, AL Amyloidosis, Diamond Blackfan Anemia, Myelofibrosis, Myeloproliferative Disease, Sickle Cell Anemia, Autoimmune Diseases, Thalassemia

Learn More ›

Assessing the Clinical Benefit of Molecular Profiling in Patients With Solid Tumors

NCT03061305

Recruiting

Many patients are treated for advanced cancer without knowledge of underlying molecular features that might indicate FDA approved therapies or potential eligibility for biomarker-selected clinical trials. The Strata Trial (STR-001-001) has been initiated by Strata Oncology to evaluate the clinical benefit of systematic comprehensive genomic profiling for participants with advanced cancer using real-world data and endpoints, while assessing the proportion of participants available for clinical t... Read More

Gender:

All

Ages:

18 years and above

Trial Updated:

02/23/2023

Locations: University of Alabama, Birmingham, Birmingham, Alabama +39 locations

University of Alabama, Birmingham, Birmingham, Alabama

Kaiser Permanente - Southern California, Pasadena, California

Kaiser Permanente - Northern California, Vallejo, California

SCL Health, Broomfield, Colorado

Kaiser Permanente Colorado, Denver, Colorado

Christiana Care Health System, Newark, Delaware

SwedishAmerican, Rockford, Illinois

Baptist Health, Lexington, Kentucky

Christus Health, Lake Charles, Louisiana

Ochsner Clinic Foundation, New Orleans, Louisiana

Kaiser Permanente - Mid-Atlantic, Rockville, Maryland

Minnesota Oncology - Burnsville, Burnsville, Minnesota

Minnesota Oncology - Coon Rapids, Coon Rapids, Minnesota

Fairview Southdale Hospital, Edina, Minnesota

Minnesota Oncology - Maplewood Cancer Center, Maplewood, Minnesota

St. John's Hospital, Maplewood, Minnesota

Metro-Minnesota Community Oncology Research Consortium, Minneapolis, Minnesota

Regions Hospital, Minneapolis, Minnesota

Minnesota Oncology - Minneapolis, Minneapolis, Minnesota

North Memorial Health Care, Robbinsdale, Minnesota

Park Nicollet Health Services, Saint Louis Park, Minnesota

Minnesota Oncology - Edina, Saint Louis Park, Minnesota

Minnesota Oncology - Woodbury Clinic, Woodbury, Minnesota

North Mississippi Medical Center, Tupelo, Mississippi

University of North Carolina, Chapel Hill, Chapel Hill, North Carolina

Hayworth Cancer Center, High Point, North Carolina

UNC REX Healthcare, Raleigh, North Carolina

Kettering Health Network, Kettering, Ohio

Kaiser Permanente Northwest, Portland, Oregon

Lehigh Valley Health Network, Allentown, Pennsylvania

Prisma Health Cancer Institute, Greenville, South Carolina

Bon Secours St. Francis, Greenville, South Carolina

UTHealth - Memorial Hemann Cancer Institute, Houston, Texas

Bon Secours Midlothian, Midlothian, Virginia

MultiCare, Tacoma, Washington

Gundersen Health System, La Crosse, Wisconsin

University of Wisconsin, Madison, Wisconsin

Marshfield Clinic, Marshfield, Wisconsin

Aurora Research Institute, Milwaukee, Wisconsin

ProHealth Care, Waukesha, Wisconsin

Conditions: Cancer, Adult Solid Tumor, Lymphoma, Multiple Myeloma

Learn More ›

A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma

NCT05028348

Recruiting

This phase 3 randomized, open-label multicenter trial will compare the efficacy, safety and the impact on health-related quality of life (HR-QoL) of SPd versus EloPd in pomalidomide-naïve patients with MM who have received 1 to 4 prior anti-MM regimens and been treated with an immunomodulatory imide drug (IMiD), proteasome inhibitor (PI) and an anti-CD38 monoclonal antibody (mAb).

Gender:

All

Ages:

18 years and above

Trial Updated:

02/20/2023

Locations: The University of Arizona Cancer Center, Tucson, Arizona +67 locations

The University of Arizona Cancer Center, Tucson, Arizona

University of California, San Francisco, Fresno, California

Kaiser Permanente Southern California, Irvine, California

Los Angeles Hematology Oncology Medical Group, Los Angeles, California

Berenson Oncology, West Hollywood, California

The Oncology Institute of Hope and Innovation, Whittier, California

UCHealth Cancer Center - Harmony Campus, Fort Collins, Colorado

Florida Cancer Specialists South, Fort Myers, Florida

Florida Cancer Specialists North, Saint Petersburg, Florida

Florida Cancer Specialists Panhandle, Tallahassee, Florida

Florida Cancer Specialists East, West Palm Beach, Florida

Hawaii Cancer Care, Honolulu, Hawaii

June E. Nylen Cancer Center, Sioux City, Iowa

Hematology Oncology Clinic, Baton Rouge, Louisiana

American Oncology Partners of Maryland, Bethesda, Maryland

Ascension St. John Hospital, Grosse Pointe Woods, Michigan

Nebraska Hematology - Oncology, P.C., Lincoln, Nebraska

Cancer Care Specialists, Reno, Nevada

MD Anderson Cancer Center at Cooper, Camden, New Jersey

East Carolina University, Greenville, North Carolina

Novant Health Cancer Institute, Winston-Salem, North Carolina

Reading Hospital - McGlinn Cancer Institute, West Reading, Pennsylvania

Medical University of South Carolina. Hollings Cancer Center, Charleston, South Carolina

Gibbs Cancer Center, Spartanburg, South Carolina

Renovatio Clinical Research, The Woodlands, Texas

CHRU Hôpital Claude Huriez, Lille, Not set

CHRU Hôtel Dieu, Nantes, Not set

CHU Hôpital Saint Antoine, Paris, Not set

La Pitié, Paris, Not set

Paris Necker, Paris, Not set

CHU Poitiers - Pôle régional de Cancérologie, Poitiers, Not set

Pôle IUCT Oncopole CHU, Toulouse, Not set

Universitätsklinikum Hamburg - Eppendorf, Hamburg, Not set

University Hospital of Heidelberg, Heidelberg, Not set

University Hospital of Cologne, Köln, Not set

University Hospital of Münster, Münster, Not set

University Hospital of Würzburg, Würzburg, Not set

Alexandra General Hospital -Department of Clinical Therapeutics N.K. Univ. of Athens, Athens, Not set

General Hospital of Athens"Evangelismos", Athens, Not set

St Savvas Cancer Hospital, Athens, Not set

University General Hospital of Patras, Patras, Not set

Theagenion Cancer Hospital, Thessaloníki, Not set

Azienda Ospedaliero-Universitaria Ospedali Riuniti Umberto I - G.M. Lancisi - G. Salesi Di Ancona, Ancona, Not set

A.O. Papa Giovanni XXIII, Bergamo, Not set

Bologna, Bologna, Not set

ASST Spedali Civili di Brescia - Ematologia, Brescia, Not set

Brescia, Brescia, Not set

Ospedale Oncologico 'A. Businco', Cagliari, Not set

Az.Osp. Di Careggi_Dh ematologia, Firenze, Not set

A.O.U. Policlinico S. Martino - Ematologia, Genova, Not set

Hospital IRST, Meldola, Not set

A.O.U. Policlinico 'G. Martino', Messina, Not set

A.O.U. Maggiore della Carità di Novara, Novara, Not set

Ospedale S. Eugenio, Roma, Not set

A.O. S. Maria, Terni, Not set

A.O.U. Città della Salute e della Scienza di Torino - SC Ematologia U, Torino, Not set

Azienda Ospedaliera Universitaria di Udine, Udine, Not set

Amphia ziekenhuis, Breda, Not set

Erasmus MC, Rotterdam, Not set

Hospital Clinic I Provincial de Barcelona, Barcelona, Not set

Institut Catala D Oncolocia Hospitalet - Hospital Duran i Reynals, Barcelona, Not set

Hospital Universitario 12 de Octubre, Madrid, Not set

H. General Universitario Morales Meseguer, Murcia, Not set

Clínica Universidad de Navarra (CUN), Pamplona, Not set

Hospital Universitario de Salamanca, Salamanca, Not set

H. Universitario Marqués de Valdecilla, Santander, Not set

Complejo Hospitalario Universitario de Santiago (CHUS), Santiago De Compostela, Not set

H.U. La Fe, Valencia, Not set

Conditions: Multiple Myeloma

Learn More ›

Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)

NCT01838512

Recruiting

The purpose of this study is to assess the clinical effectiveness of all approved multiple myeloma (MM) therapies in the newly-diagnosed (NDMM) and the relapsed/refractory MM (RRMM) settings in real-world clinical practice.

Gender:

All

Ages:

18 years and above

Trial Updated:

02/16/2023

Locations: Local Institution, Birmingham, Alabama +191 locations

Local Institution, Birmingham, Alabama

Local Institution - 0021, Birmingham, Alabama

Local Institution - 0013, Muscle Shoals, Alabama

Local Institute, Goodyear, Arizona

Local Institution, Anaheim, California

Pacific Cancer Madical Center, Anaheim, California

East Valley Hematology And Oncology Medical Group, Burbank, California

Local Institution, Corona, California

The Oncology Institute Of Hope And Innovation, Downey, California

Compassionate Cancer Care Medical Group, Fountain Valley, California

Local Institute, Los Angeles, California

Local Institute, Santa Rosa, California

St Joseph Heritage Healthcare, Santa Rosa, California

Local Institution - 0057, Washington, District of Columbia

Florida Cancer Specialists & Research Institute, Brooksville, Florida

Local Institution, Brooksville, Florida

Michael and Dianne Bienes Cancer Center, Fort Lauderdale, Florida

Local Institution - 0017, Jacksonville, Florida

Local Institution, Jacksonville, Florida

Summit Cancer Care, Savannah, Georgia

Local Institute, Valdosta, Georgia

Pearlman Cancer Center, Valdosta, Georgia

Local Institution, Skokie, Illinois

SIU Simmons Cancer Institute, Springfield, Illinois

Local Institution - 0012, Urbana, Illinois

St. Vincent Anderson Regional Hospital, Anderson, Indiana

Indiana Blood and Marrow Transplantation LLC, Indianapolis, Indiana

Local Institution, Indianapolis, Indiana

Local Institution - 0061, Des Moines, Iowa

Local Institute, Sioux City, Iowa

Local Institution - 0018, Sioux City, Iowa

Local Institution - 0062, Lexington, Kentucky

Local Institution - 0064, London, Kentucky

Local Institute, Louisville, Kentucky

Norton Cancer Institute, Louisville, Kentucky

Cancer Center of Acadiana at Lafayette General Health, Lafayette, Louisiana

Local Institution, Lafayette, Louisiana

Local Institution - 0009, Shreveport, Louisiana

Local Institution, Shreveport, Louisiana

Local Institution, Minneapolis, Minnesota

Minnesota Oncology Hematology, P.A., Woodbury, Minnesota

Local Institution - 0059, Jackson, Mississippi

Local Institute, Southaven, Mississippi

Local Institute, Kansas City, Missouri

Research Medical Center, Kansas City, Missouri

Montana Cancer Institute Foundation, Missoula, Missouri

Local Institute, Saint Joseph, Missouri

Local Institution - 0015, Saint Louis, Missouri

Local Institution, Saint Louis, Missouri

Local Institution, Springfield, Missouri

Mercy Medical Research Institute, Springfield, Missouri

Local Institute, Missoula, Montana

Local Institution - 0060, Lincoln, Nebraska

Local Institute, Omaha, Nebraska

Oncology Hematology West, P.C., Omaha, Nebraska

Bms Clinical Research Center, Does Not Exist, New Jersey

Stony Brook University Hospital, Stony Brook, New York

Local Institute, Cary, North Carolina

Waverly Hematology Oncology, Cary, North Carolina

Gaston Hematology & Oncology, Gastonia, North Carolina

Local Institution, Gastonia, North Carolina

Gabrail Cancer Center Research, Canton, Ohio

Local Institute, Canton, Ohio

Local Institute, Cleveland, Ohio

Local Institution - 0019, Cleveland, Ohio

Local Institute, Tulsa, Oklahoma

Tulsa Cancer Institute PLLC, Tulsa, Oklahoma

Local Institute, Portland, Oregon

Local Institute, Pottstown, Pennsylvania

Pottstown Hospital Tower Health - Oncology, Pottstown, Pennsylvania

Charleston Oncology, Charleston, South Carolina

Local Institute, Charleston, South Carolina

Local Institute, Knoxville, Tennessee

University of Tennessee Medical Center, Knoxville, Tennessee

Baptist Cancer Center, Memphis, Tennessee

Local Institution, Memphis, Tennessee

Local Institute, Amarillo, Texas

Local Institution - 0029, Amarillo, Texas

Local Institution - 0063, Bryan, Texas

Local Institute, Corpus Christi, Texas

Local Institute, Dallas, Texas

Dallas Presbyterian Hospital - Texas Oncology PA, Dallas, Texas

Local Institute, Dallas, Texas

UT Southwestern Medical Center, Dallas, Texas

Texas Oncology-Garland, Garland, Texas

Cancer Care Centers Of South Texas, San Antonio, Texas

Local Institute, San Antonio, Texas

Local Institute, Sherman, Texas

Local Institution - 0028, Sherman, Texas

Local Institute, Seattle, Washington

VA Puget Sound Health Care System, Seattle, Washington

Cancer Care Northwest, Spokane, Washington

Local Institute, Spokane, Washington

Local Institute, Yakima, Washington

Yakima Valley Memorial Hospital, Yakima, Washington

Local Institution - 0065, Toronto, Ontario

Local Institute, Toronto, Ontario

Local Institution - 0066, Toronto, Ontario

Local Institute, Weston, Ontario

Local Institute, Blois, Not set

Local Institution - 0106, Cannes Cedex, Not set

Local Institution - 0099, Chalon sur Saone, Not set

Local Institute, Chalon sur Saone, Not set

Local Institute, La Roche sur Yon, Not set

Local Institution - 0100, La Roche-sur-yon Cedex 9, Not set

Local Institution - 0104, Limoges, Not set

Local Institute, Limoges, Not set

Local Institution - 0105, Meaux, Not set

Local Institute, Meaux, Not set

Local Institution - 0102, Nantes, Not set

Local Institute, Nantes, Not set

Local Institution - 0101, Perigueux, Not set

Local Institute, Rennes, Not set

Local Institution - 0103, Rennes, Not set

Local Institute, Heidelberg, Baden-Württemberg

Local Institute, Hamm, Nordrhein-Westfalen

Local Institute, Aschaffenburg, Not set

Local Institution - 0072, Aschaffenburg, Not set

Local Institute, Berlin, Not set

Local Institution - 0068, Berlin, Not set

Local Institution - 0081, Bielefeld, Not set

Local Institution, Bochum, Not set

Local Institute, Dresden, Not set

Local Institution - 0069, Dresden, Not set

Local Institution - 0082, Dresden, Not set

Local Institution - 0077, Frankfurt-oder, Not set

Local Institution - 0084, Gelsenkirchen, Not set

Local Institution - 0089, Goslar, Not set

Local Institution - 0070, Hamm, Not set

Local Institution - 0071, Heidelberg, Not set

Local Institution - 0088, Kiel, Not set

Local Institution - 0087, Köln, Not set

Local Institution - 0076, Ludwigsburg, Not set

Local Institute, Magdeburg, Not set

Local Institution - 0067, Magdeburg, Not set

Local Institution - 0073, Muenchen, Not set

Local Institution - 0079, Mutlangen, Not set

Local Institute, München, Not set

Local Institution - 0080, Oldenburg, Not set

Local Institution - 0075, Reutlingen, Not set

Local Institution - 0074, Rostock, Not set

Local Institution - 0086, Rostock, Not set

Local Institute, Rostock, Not set

Local Institution - 0078, Traunstein, Not set

Local Institution - 0085, Wiesbaden, Not set

Local Institute, Pesaro, Pesaro E Urbino

Local Institute, Ancona, Not set

Local Institution - 0108, Ancona, Not set

Local Institute, Ancona, Not set

Local Institution - 0119, Cagliari, Not set

Local Institute, Cagliari, Not set

Local Institution - 0111, Firenze, Not set

Local Institute, Firenze, Not set

Local Institute, Lecce, Not set

Local Institution - 0113, Lecce, Not set

Local Institution - 0124, Messina, Not set

Local Institution - 0120, Messina, Not set

Local Institute, Milano, Not set

Local Institution - 0116, Milano, Not set

Local Institute, Napoli, Not set

Local Institution - 0114, Napoli, Not set

Local Institution - 0115, Pesaro, Not set

Local Institution - 0121, Pescara, Not set

Local Institute, Roma, Not set

Local Institution - 0109, Roma, Not set

Local Institution - 0110, Roma, Not set

Local Institution - 0118, Roma, Not set

Local Institution, Roma, Not set

Local Institution - 0122, San Giovanni Rotondo (FG), Not set

Local Institution - 0107, Terni, Not set

Local Institute, Terni, Not set

Local Institute, Torino, Not set

Local Institution - 0112, Torino, Not set

Local Institute, Vicenza, Not set

Local Institution - 0117, Vicenza, Not set

Local Institute, Truro, Cornwall

Local Institution - 0098, Harrow, Not set

Local Institute, Leeds, Not set

Local Institution - 0092, Leeds, Not set

Local Institution - 0091, Liverpool, Not set

Local Institution, Liverpool, Not set

Local Institution - 0097, Manchester, Not set

Local Institute, Nottingham, Not set

Local Institution - 0095, Nottingham, Not set

Local Institute, Stafford, Not set

Local Institution - 0096, Stafford, Not set

Local Institute, Swansea, Not set

Local Institution - 0093, Swansea, Not set

Local Institution - 0094, Truro, Not set

Conditions: Multiple Myeloma

Learn More ›

Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy

NCT05646576

Recruiting

The goal of this study is to determine whether a palliative care intervention (PEACE) can improve the quality of life and experiences of participants with Lymphoma, Leukemia, or Multiple Myeloma receiving adoptive cellular therapy (ACT). After completion of an open pilot, participants will be randomly assigned into one of two study intervention groups. The names of the study intervention groups involved in this study are: Palliative care (PEACE) plus usual oncology care Usual care (standard on... Read More

Gender:

All

Ages:

18 years and above

Trial Updated:

01/24/2023

Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts

Conditions: Hematologic Malignancy, Blood Cancer, Lymphoma, Leukemia, Multiple Myeloma

Learn More ›

Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory Multiple Myeloma

NCT05007418

Recruiting

This is a phase 1b, open-label, dose-escalation study of STI-1492 administered by a single intravenous infusion in subjects with relapsed or refractory multiple myeloma.

Gender:

All

Ages:

18 years and above

Trial Updated:

01/12/2023

Locations: UC Irvine, Orange, California +2 locations

Conditions: Multiple Myeloma

Learn More ›

A Study of Belantamab Mafodotin Monotherapy in Multiple Myeloma Participants With Normal and Varying Degree of Impaired Renal Function

NCT04398745

Recruiting

Belantamab mafodotin is an antibody-drug conjugate (ADC) containing humanized anti- B-cell maturation antigen (BCMA) monoclonal antibody (mAb). Renal impairment is a major complication of multiple myeloma (MM) and the majority of MM participants is either at risk or already has renal dysfunction at initial diagnosis. The purpose of this study is to assess the pharmacokinetics (PK), safety, and tolerability of belantamab mafodotin monotherapy in participants with RRMM, who have had at least 3 lin... Read More

Gender:

All

Ages:

18 years and above

Trial Updated:

11/01/2022

Locations: GSK Investigational Site, Tucson, Arizona +25 locations

Conditions: Multiple Myeloma

Learn More ›